D5817
DMXAA
≥98% (HPLC), solid, apoptosis inducer
别名:
5,6-二甲基黄嘌呤-4-乙酸, ASA404, Vadimezan
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C17H14O4
CAS Number:
分子量:
282.29
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
Product Name
DMXAA, ≥98% (HPLC), solid
质量水平
方案
≥98% (HPLC)
表单
solid
颜色
light brown
溶解性
DMSO: soluble >10 mg/mL
储存温度
2-8°C
SMILES字符串
Cc1ccc2C(=O)c3cccc(CC(O)=O)c3Oc2c1C
InChI
1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
InChI key
XGOYIMQSIKSOBS-UHFFFAOYSA-N
相关类别
一般描述
5,6-二甲基呫吨酮-4-乙酸（DMXAA）是一种黄酮乙酸衍生物。可作为血管破坏剂（VDA）起作用，破坏肿瘤血管系统并产生抗肿瘤免疫应答。能引起出血性坏死。
应用
5,6-二甲基呫吨酮-4-乙酸（DMXAA）用于以干扰素基因刺激因子（STING）依赖的方式诱导 I 型 IFN 信号传导。在未感染的情况下，也用于研究 STING 依赖性信号传导。
生化/生理作用
DMXAA是一种细胞凋亡诱导剂；抗血管。
特点和优势
该化合物是细胞凋亡研究的推荐产品。点击这里 发现更多精选的细胞凋亡产品。了解更多有关用于其他研究领域的生物活性小分子的信息，请访问 sigma.com/discover-bsm。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Aquatic Acute 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
Weiss JM, et al.
Oncoimmunology, 6(10), e1346765-e1346765 (2017)
Jing Sun et al.
Biochemical pharmacology, 82(9), 1175-1185 (2011-08-09)
The small molecule anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA, now called Vadimezan) is a potent macrophage and dendritic cell activating agent that, in the murine system, results in the release of large amounts of cytokines and chemokines. The mechanisms by which
S M Tijono et al.
British journal of cancer, 108(6), 1306-1315 (2013-03-14)
Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were so promising. To identify analogues with greater human clinical potential, we
Primo N Lara et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(22), 2965-2971 (2011-06-29)
This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients with advanced stage IIIB
Z G Fridlender et al.
British journal of cancer, 108(6), 1288-1297 (2013-03-14)
Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy. We and others have reported
商品
Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.
Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持